PL1940353T3 - Fotochemicznie trwała kompozycja farmaceutyczna zawierająca brywudynę do leczenia opryszczkowego zapalenia rogówki - Google Patents

Fotochemicznie trwała kompozycja farmaceutyczna zawierająca brywudynę do leczenia opryszczkowego zapalenia rogówki

Info

Publication number
PL1940353T3
PL1940353T3 PL06805904T PL06805904T PL1940353T3 PL 1940353 T3 PL1940353 T3 PL 1940353T3 PL 06805904 T PL06805904 T PL 06805904T PL 06805904 T PL06805904 T PL 06805904T PL 1940353 T3 PL1940353 T3 PL 1940353T3
Authority
PL
Poland
Prior art keywords
treatment
pharmaceutical composition
composition containing
herpetic keratitis
containing brivudine
Prior art date
Application number
PL06805904T
Other languages
English (en)
Inventor
Marc Wihsmann
Reinhard Schmitz
Original Assignee
Berlin Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Chemie Ag filed Critical Berlin Chemie Ag
Publication of PL1940353T3 publication Critical patent/PL1940353T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL06805904T 2005-09-29 2006-09-27 Fotochemicznie trwała kompozycja farmaceutyczna zawierająca brywudynę do leczenia opryszczkowego zapalenia rogówki PL1940353T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005046769A DE102005046769A1 (de) 2005-09-29 2005-09-29 Lichtstabile, brivudinhaltige pharmazeutische Formulierung zur Behandlung von Augenherpes (Herpes Ophthalmicus)
PCT/EP2006/009383 WO2007039201A2 (en) 2005-09-29 2006-09-27 Photostable pharmaceutical composition containing brivudine for the treatment of herpetic keratitis
EP06805904A EP1940353B1 (en) 2005-09-29 2006-09-27 Photostable pharmaceutical composition containing brivudine for the treatment of herpetic keratitis

Publications (1)

Publication Number Publication Date
PL1940353T3 true PL1940353T3 (pl) 2011-05-31

Family

ID=37561306

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06805904T PL1940353T3 (pl) 2005-09-29 2006-09-27 Fotochemicznie trwała kompozycja farmaceutyczna zawierająca brywudynę do leczenia opryszczkowego zapalenia rogówki

Country Status (33)

Country Link
US (1) US20080249061A1 (pl)
EP (1) EP1940353B1 (pl)
JP (1) JP2009509993A (pl)
KR (1) KR20080053319A (pl)
CN (1) CN101272765A (pl)
AP (1) AP2008004394A0 (pl)
AR (1) AR056551A1 (pl)
AT (1) ATE489076T1 (pl)
AU (1) AU2006299115A1 (pl)
BR (1) BRPI0616449A2 (pl)
CA (1) CA2624111A1 (pl)
CR (1) CR9839A (pl)
CY (1) CY1111059T1 (pl)
DE (2) DE102005046769A1 (pl)
DK (1) DK1940353T3 (pl)
EA (1) EA012975B1 (pl)
EC (1) ECSP088310A (pl)
ES (1) ES2356774T3 (pl)
HN (1) HN2008000497A (pl)
HR (1) HRP20110085T1 (pl)
IL (1) IL190466A0 (pl)
MA (1) MA29887B1 (pl)
NO (1) NO20081488L (pl)
PE (1) PE20070767A1 (pl)
PL (1) PL1940353T3 (pl)
PT (1) PT1940353E (pl)
RS (1) RS51615B (pl)
SI (1) SI1940353T1 (pl)
TN (1) TNSN08094A1 (pl)
TW (1) TW200744664A (pl)
UA (1) UA90911C2 (pl)
WO (1) WO2007039201A2 (pl)
ZA (1) ZA200802729B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006130A2 (en) * 2007-06-28 2009-01-08 Bausch & Lomb Incorporated Salt free hyaluronate ophthalmic solution
US20090196833A1 (en) * 2008-02-06 2009-08-06 Adherex Technologies Inc. Compositions comprising topical dpd inhibitors and methods of using same in the treatment of hand-foot syndrome
DE102009003942A1 (de) * 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
EP2898888B8 (en) 2014-01-22 2019-06-12 VISUfarma B.V. Composition comprising iota-carrageenan against viral Conjunctivitis
WO2017192944A1 (en) * 2016-05-06 2017-11-09 SaCSh Corp. Ophthalmic compositions
CN113712928A (zh) * 2021-09-29 2021-11-30 重庆市力扬医药开发有限公司 经口腔粘膜吸收的溴夫定药物
EP4623919A1 (en) 2024-03-28 2025-10-01 Marinomed Biotech AG Composition comprising iota-carrageenan for the treatment of dry eyes, non-viral conjunctivitis and allergic ocular conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY136633A (en) * 2001-01-17 2008-11-28 Berlin Chemie Ag Stabilized brivudine topical formulations
DE10162593A1 (de) * 2001-12-19 2003-07-03 Menarini Ricerche Spa Stabilisierte topische Brivudin-Formulierungen

Also Published As

Publication number Publication date
PE20070767A1 (es) 2007-08-13
AU2006299115A1 (en) 2007-04-12
HRP20110085T1 (hr) 2011-03-31
WO2007039201A2 (en) 2007-04-12
KR20080053319A (ko) 2008-06-12
NO20081488L (no) 2008-03-26
ECSP088310A (es) 2008-05-30
CR9839A (es) 2008-10-31
DE602006018505D1 (de) 2011-01-05
EP1940353A2 (en) 2008-07-09
HN2008000497A (es) 2010-09-10
AU2006299115A2 (en) 2008-05-29
RS51615B (sr) 2011-08-31
AR056551A1 (es) 2007-10-10
TW200744664A (en) 2007-12-16
MA29887B1 (fr) 2008-10-03
US20080249061A1 (en) 2008-10-09
BRPI0616449A2 (pt) 2011-06-21
UA90911C2 (ru) 2010-06-10
AP2008004394A0 (en) 2008-04-30
ATE489076T1 (de) 2010-12-15
EA012975B1 (ru) 2010-02-26
DE102005046769A1 (de) 2007-04-05
DK1940353T3 (da) 2011-01-24
ES2356774T3 (es) 2011-04-13
JP2009509993A (ja) 2009-03-12
ZA200802729B (en) 2009-09-30
EP1940353B1 (en) 2010-11-24
WO2007039201A3 (en) 2007-10-04
CA2624111A1 (en) 2007-04-12
IL190466A0 (en) 2008-11-03
CY1111059T1 (el) 2015-06-11
TNSN08094A1 (en) 2009-07-14
PT1940353E (pt) 2011-02-25
SI1940353T1 (sl) 2011-03-31
EA200800646A1 (ru) 2008-10-30
CN101272765A (zh) 2008-09-24

Similar Documents

Publication Publication Date Title
IL187999A0 (en) Compositions for the treatment of persistent infections
EP1871331A4 (en) COMPOSITION FOR THE TREATMENT OF MENOPAUSE
IL191832A0 (en) Pyridiazinone derivatives for the treatment of tumours
IL191141A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL186665A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL187434A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL190920A0 (en) Compounds for the treatment of metabolic disorders
IL194242A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
SI2266961T1 (sl) Postopek za sintezo organskih spojin
IL187748A0 (en) Pharmaceutical compositions containing misoprostal
IL190466A0 (en) Photostable pharmaceutical composition containing brivudine for the treatment of herpetic keratitis
EP1871363A4 (en) COMBINED STAGE PROCESS FOR PHARMACEUTICAL COMPOSITIONS
IL186252A0 (en) Pharmaceutical compositions containing melatonin derivatives
IL188831A0 (en) Compositions for reducing the incidence of drug induced arrhythmia
PL1968996T3 (pl) Sposób wytwarzania żelazo-sukcynylokazeiny
PL1976522T5 (pl) Kompozycja farmaceutyczna zawierająca montelukast
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
ZA200709621B (en) Process for the synthesis of organic compounds
IL200192A0 (en) Composition useful for the treatment of type 2 diabetes
IL185076A0 (en) Process for the prepartion of enantiomerically pure 1-substituted-3-aminoalcohols
ZA200709959B (en) Triazine compounds and compositions thereof for the treatment of cancers
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
HUP0500685A2 (en) Pharmaceutical composition for the treatment of psychosis
HUP0500947A2 (en) Composition for treatment of paradontosis
ZA200706203B (en) Processes and compounds for the preparation of substituted naphthylindole derivatives